Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

2 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

5 recruiting

Enrollment Performance

Analytics

N/A

3(42.9%)

Phase 2

2(28.6%)

Phase 3

1(14.3%)

Phase 4

1(14.3%)

7Total

N/A(3)

Phase 2(2)

Phase 3(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT06284642Phase 4Recruiting

Early Lumbar Drainage Plus Intrathecal Urokinase in Severe Aneurysmal Subarachnoid Hemorrhage (LD-ITUK)

Role: collaborator

NCT06265051Phase 2Completed

Tirofiban After Successful MT Recanalization in AIS

Role: collaborator

NCT07361783Not ApplicableRecruiting

Impact of Pre-Hospital Heparin Loading in STEMI Patients for Primary PCI: The HELP-PCI 2 Trial

Role: collaborator

NCT06943729Recruiting

Clinical Safety and Efficacy of Flow-diverter in the Treatment of Intracranial Aneurysms

Role: collaborator

NCT05329155Not ApplicableCompleted

Early Administration of Heparin At FMC for PPCI of STEMI Patients

Role: collaborator

NCT06345365Phase 3Recruiting

MA+AZA Regimen for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)

Role: collaborator

NCT05406830Not ApplicableRecruiting

Efficacy Study of Acupuncture on Asymptomatic Hyperuricemia

Role: collaborator

NCT03154983Phase 2Unknown

The Clinical Research of Mesylate Apatinib Combined With Docetaxel and S-1 as the First-line Treatment of Metastatic Gastric Cancer

Role: collaborator

All 8 trials loaded